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Objective: The purpose of this study was to review the risk-benefit ratio of 
mitral valve repair in patients with severe mitral regurgitation and no or 
mild symptoms. Methods: From January 1989 to December 1994, 584 
patients were operated on for mitral regurgitation. Of these, 175 patients 
were in New York Heart Association class I or II with grade 3 to 4 isolated 
chronic mitral regurgitation. They comprise our study population. Mean 
age was 51.3 -- 14.3 years. Principal causes of mitral regurgitation were 
degenerative in 128 (73%) and rheumatic in 26 patients (15%). Leaflet 
prolapse was the mechanism responsible for regurgitation in 152 patients 
(86%). Mitral valve repair was performed in 174 patients, and one patient 
required initial valve replacement. Mean follow-up was 34.3 -- 18.8 months. 
Results: Three patients died, for an overall mortality of 1.7%. Five patients 
were reoperated on, for an actuarial freedom from reoperation of 97.0% + 
0.8% at 5 years. Actuarial freedom from thromboembolism and endocardi- 
tis was 96.3% -+ 1.7% and 99.4% ± 0.6%, respectively, for an event-free 
survival of 91.0% ± 2.0% at 5 years. Left atrial diameter decreased from 
54.3 - 11.6 mm to 43.6 ± 10.5 mm (p < 0.001). Left ventricular end-systolic 
and end-diast01ic diameters decreased from 40.0 ± 6.8 mm and 64.8 - 7.0 
mm to 34.6 - 6.7 mm (p < 0.001) and 52.7 ± 7.4 mm (p < 0.001), 
respectively. Mean residual mitral regurgitation was 0.44 -+ 0.6. Conclusion: 
Mitral valve repair for chronic mitral regurgitation in patients having mild 
or no symptoms was performed with low mortality and morbidity, good 
valve function, and preserved late left ventricular performance. Early 
repair may be advocated on the basis of severity of regurgitation and valve 
repairability, regardless of symptoms. (J Thorac Cardiovasc Surg 1996;112: 
1240-9) 
T he optimal timing for surgical intervention in mitral regurgitation is still controversial. The 
difficulty in deciding when to operate on patients 
with chronic mitral regurgitation stems from the fact 
that mitral regurgitation may remain asymptomatic 
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or mildly symptomatic for a long time, albeit with 
progressive but silent deterioration i  left ventricu- 
lar (LV) function. 1 By the time symptoms become 
apparent, serious and sometimes irreversible LV 
dysfunction may have developed. The absence of 
simple, load-independent LV function indexes also 
contributes to the difficulty in deciding when to 
operate on patients with mitral regurgitation and 
has stimulated the search for more discriminating 
and easy methods that could help in the optimal 
timing for surgery) 
Recognition of the advantages of valve repair 
over valve replacement for mitral regurgitation has 
progressively ed to earlier surgical intervention)' 4 
Most authors now advocate surgical intervention for 
severe mitral regurgitation even for patients in New 
York Heart Association (NYHA) class II so long as 
the ventricle is dilated and the valve seems repair- 
able.5, 6 Because echocardiography can reliably pre- 
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Table I. Causes of mitral regurgitation 
Cause No. % 
Degenerative 128 73 
Rheumatic 26 15 
Endocarditis 19 11 
Miscellaneous 2 1 
dict the feasibil ity of valve repair,  it has been our 
policy to surgically correct mitral  valve insufficiency 
solely on the basis of the severity of regurgitation, 
irrespective of symptoms. 7 However,  the clinical 
impact of surgical correct ion of mitral  regurgitat ion 
in pat ients with no symptoms or only mild symptoms 
is still uncertain in terms of outcome. Accordingly,  
we have reviewed our experience with the surgical 
management  of isolated severe mitral  regurgitat ion 
in pat ients with no symptoms or mild symptoms to 
assess the following: criteria for deciding on surgery, 
valve repai r / rep lacement  ratio, surgical as well as 
valve-related mortal i ty and morbidity, and effect on 
late LV function. 
Patients and methods 
This study was based on a retrospective r view of a 
three-institution experience with surgical correction of 
isolated mitral regurgitation i  patients with no symptoms 
or mild symptoms. We reviewed the clinical case histories, 
operative notes, and laboratory investigations including 
electrocardiograms, echocardiograms, and cardiac cathe- 
terization data. 
The inclusion criteria were as follows: 
1. Surgical correction of mitral regurgitation between 
January 1989 and December 1994. 
2. Preoperative functional class I or II according to the 
NYHA classification. The patient's functional status was 
determined by analysis of chart records. Patients were 
considered to have NHYA class I disease if they had no 
limitation of physical activity and no symptoms. NYHA 
class II was designated when there was slight limitation of 
physical activity with dyspnea on effort, for example, 
climbing more than one flight of ordinary stairs at a steady 
pace. 
3. Isolated, severe mitral regurgitation with no or 
minimal associated mitral stenosis as defined by preoper- 
ative echocardiography. 
The exclusion criteria were as follows: 
1. Mitral regurgitation caused by dilated or ischemic 
cardiomyopathy. 
2. Acute mitral regurgitation of recent onset with an 
episode of pulmonary edema occurring less than 3 months 
before the operation. 
3. Associated or previous urgical procedures: coronary 
artery bypass grafting; valve replacement or repair other 
than tricuspid valve repair. 
During the study period, 584 consecutive patients had 
mitral valve operations for mitral regurgitation in the 
three institutions; 520 patients had valve repair (89%) and 
Table II. Principal mechanisms of mitral 
regurgitation 
Functional 
Mechanism type No. % 
Restricted leaflet motion 
Leaflet prolapse 
Prolapse + restriction 
Annular dilatation 
Others 
I 8 4.6 
II 152 86.8 
Anterior 19 
Posterior 86 
Double 47 
III 9 5.2 
IV 3 1.7 
3 1.7 
64 had valve replacement (11%). Of these, 175 patients 
did correspond to the inclusion-exclusion criteria, and 
they comprise our study population. Patients were oper- 
ated on at Clinique La Roseraie (n = 73) and H6pital 
Foch (n = 29), Paris, France, and Clinica Villa Maria (n = 
73), Cotignola, Italy, by two surgeons. 
The mean age was 51.3 _+ 14.3 years. There were 121 
men (69%) and 54 women. Fifty-three patients were in 
NYHA class I (30%) and 122 were in NYHA class II 
(70%). Data on preoperative medical treatment were 
available in 81 patients (46%): 28% had no preoperative 
medical treatment, 40% had digitalis or diuretic therapy, 
and 32% had multiple drug therapy. Preoperatively, 123 
patients were in sinus rhythm (70%), 35 patients (20%) 
were in atrial fibrillation, 15 (9%) had prior episodes of 
atrial fibrillation, and in two patients information regard- 
ing the cardiac rhythm was unavailable. Patients with 
preoperative atrial fibrillation as compared with patients 
in sinus rhythm were older (58.7 -+ 11.5 years vs 49.4 -+ 
14.4 years; p < 0.001) and had larger left atrial diameters 
(61.6 _+ 13.0 vs 52.6 +- 9.4 mm;p < 0.001). 
Causes of mitral regurgitation are listed in Table I. The 
mechanisms of mitral regurgitation are summarized in 
Table II according to the functional classification. 8 The 
severity of mitral regurgitation was assessed either by LV 
angiography or transesophageal echocardiography. 9 LV 
diameters and volumes were measured by transthoracic 
echocardiography in the parasternal long-axis view by the 
leading edge method. 1° LV ejection fraction was calcu- 
lated as previously described. 1I All patients had grade 3+ 
or 4+ mitral regurgitation on a scale of 4 with a mean of 
3.4 _+ 0.5. LV end-systolic and end-diastolic diameters 
were 40.0 _+ 6.8 mm and 64.8 + 7.0 mm (mean -+ standard 
deviation), respectively. Mean left atrial diameter was 
54.3 + 11.6 mm. Of 151 patients who had preoperative 
recording of end-diastolic diameter, 111 (73%) had an LV 
end-diastolic diameter greater than 60 and 29 had an 
end-diastolic diameter greater than 70 (19%). Forty-seven 
patients underwent preoperative right heart catheteriza- 
tion. The mean pulmonary artery pressure was 22.2 _+ 9.3 
mm Hg. 
There were no significant differences between patients 
with NYHA class I or class II disease with regard to age, 
degree of regurgitation, or left heart chamber size except 
for LV end-diastolic diameter, which was smaller in 
patients with class II disease (63.9 -+ 6.9 mm in NYHA 
class I vs 67.2 _+ 6.5 in NYHA class II; p = 0.008). 
1 2 4 2 Sousa Uva et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
November 1996 
Table I I I. Surgical procedures 
Procedures No. % 
Posterior leaflet resection 133 76 
Chordal transposition 46 26 
Chordal shortening 38 22 
Sliding repair 14 8 
Subvalvular mobilization 17 10 
Commissurotomy 12 7 
Anterior leaflet patch 2 1 
Annular decalcification 2 1 
Ring annuloplasty 174 100 
Tricuspid repair 27 15 
Mitral valve replacement 1 0.5 
No fixed protocol was followed, but in general the 
decision to operate was made when the following criteria 
were met: (1) Severe mitral regurgitation (grade 3 or 4) 
was recorded and appeared to induce progressive left 
atrial-LV dilatation or atrial arrhythmia (or both); (2) the 
patient was in good general condition without any other 
systemic diseases; and (3) the valve was deemed repair- 
able by an experienced echocardiographer. 
Of the 175 patients, 174 had initial mitral valve repair 
and one had valve replacement. Valve repair was at- 
tempted in all cases. In one patient, the decision to 
replace the valve was made during the operation because 
of severely retracted leaflets owing to rheumatic disease. 
Carpentier techniques were used for repair in all three 
institutions, 12with some modifications as previously re- 
ported, ~3 and are listed in Table III. A standard Carpen- 
tier-Edwards prosthetic ring (Baxter Healthcare Corp., 
Edwards Div., Santa Ana, Calif.) was used in 144 patients, 
and a flexible Carpentier-Edwards Physio ring (Baxter) 
was used in 28 patients. Mean crossclamp and cardiopul- 
monary bypass times were 62.8 _+ 15.5 and 90.2 _+ 20.9 
minutes, respectively. All patients received systemic anti- 
coagulation with antivitamin K therapy for the first 2 
months after the operation. After this period, discontinu- 
ation of anticoagulation was recommended for patients in 
sinus rhythm, but the decision was left to the discretion of 
the referring physician. 
Follow-up. Data were collected through questionnaires 
and telephone contacts with the patients, family physi- 
cians, and cardiologists. Long-term follow-up was ob- 
tained during a 6-month interval from July to December 
1995. Follow-up was available for 167 patients (98.1%). 
Mean follow-up was 34.3 _+ 18.8 months (median = 26.5 
months) for a cumulative follow-up of 473 patient-years. 
Results were reported according to the recommendations 
of the Ad Hoc Liaison Committee as found in the 
"Guidelines for Reporting Morbidity and Mortality After 
Cardiac Valvular Operations. ''14 
Statistical analysis. Data were expressed as mean _+ 
one standard deviation, and selected proportions were 
presented with their 70% confidence limits. X 2 Contin- 
gency tables and Student's t test were used to analyze the 
significance of differences between preoperative and post- 
operative data. The Kaplan-Meier method was used for 
calculating the actuarial survival and complication rates. 
Results 
Mortality. Three patients died during the first 30 
postoperative days, one at each of the institutions, 
for an overall hospital mortality of 1.7%. Cause of 
death was LV failure in two patients aged 73 and 58 
years, who had preoperative LV end-diastolic vol- 
ume indexes of 132 and 190 ml/m 2, respectively. 
Death in the third patient was due to a cerebral 
tumor hemorrhage occurring immediately after the 
operation. There were no late deaths. The actuarial 
survival at 5 years was 98.2% _+ 1.0% (Fig 1). 
Morbidity. Six patients required reexploration 
for bleeding. One patient had ischemic cerebral 
infarction, which eventually resolved without se- 
quelae 2 months after the operation. One patient 
required a permanent pacemaker for complete 
atrioventricular block. Two patients had systolic 
anterior motion of the anterior leaflet, detected on 
postoperative Doppler echocardiography, which was 
successfully treated pharmacologically. Thus a total 
of 10 patients had a significant morbid event for a 
cumulated mortality-morbidity rate of 7.4%. 
Reoperations. There were three early reopera- 
tions for failure of the valve repair during the 
immediate postoperative period. All three patients 
were in NYHA class II before the operation and had 
valve replacement for their failed repair. Causes for 
early reoperation were residual mitral insufficiency 
in two patients and LV outflow tract obstruction in 
another patient with Barlow's disease. There were 
two late reoperations at 3 and 5 months. The 
original etiology was rheumatic mitral disease in one 
patient and degenerative valve disease in the other 
patient. Causes for reoperation were significant 
residual eak caused by persistent restricted leaflet 
motion in one case and ring dehiscence in the 
second case, and both necessitated valve replace- 
ment. No deaths occurred during reoperation. 
At 5 years, the rate of freedom from reoperation 
was 97.0% _+ 0.8%, for a linearized rate of l%/pt-yr 
exposed to reoperation. 
Thromboembolism. Five patients had a throm- 
boembolic event, for an actuarial rate of freedom 
from thromboembol ic  complications of 96.2% _+ 
1.7% at 5 years and a linearized rate of 1.0%/pt- 
yr. One patient had an asymptomatic left atrial 
thrombus diagnosed by two-dimensional echocar- 
diography. Two patients had transient amaurosis. 
Two patients had hemiparesis that resolved with- 
out residual deficit. 
Anticoagulant-related hemorrhage. Apart from 
the already mentioned intracerebral tumor hemor- 
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Fig. 1. Actuarial survival curve (percent) as a function of time after the initial operation. Numbers above 
x axis represent number of patients available for follow-up. 
rhage, no anticoagulant-related complication was 
seen in this series. Twenty-five patients were receiv- 
ing long-term anticoagulant therapy (15.5%) at 
most recent follow-up. 
Endocarditis. One patient had valvular endocar- 
ditis and was treated with antibiotics, for an actuar- 
ial rate of freedom from endocarditis of 99.3% _+ 
0.6% at 5 years and a linearized rate of 0.2%/pt-yr. 
Event-free survival. Freedom from death, throm- 
boembolism, reoperation, and anticoagulant-related 
hemorrhage was 91.0% _+ 2.0% at 5 years (Fig 2). 
Cardiac rhythm. In 162 patients the electrocar- 
diogram was analyzed at the most recent visit. 
Twenty-three patients were in atrial fibrillation 
(14.1%), 134 were in sinus rhythm (83.3%), and five 
patients had other cardiac rhythms. Ten patients 
who were in sinus rhythm before the operation had 
atrial fibrillation at the most recent visit, whereas 17 
who were in atrial fibrillation before the operation 
had sinus rhythm during follow-up (Fig. 3). 
Functional status. A total of 145 patients were in 
NYHA class I (86.8%), 21 were in NYHA class II 
(12.5%), and one patient was in NYHA class III 
(0.5%). In 150 patients, information could be ob- 
tained regarding medical therapy. One hundred four 
patients (69.3%) had no medical therapy (vs 28% 
before the operation); 27 patients were receiving 
one medication (18.0%) and 19 patients (12.6%) 
were on a double drug regimen. 
Echocardiographic results. Two-dimensional echo- 
cardiography and Doppler examination were available 
in 140 patients at latest follow-up (83.3%). The echo- 
cardiographic data before and after operation showed 
that all left heart chamber dimensions decreased sig- 
nificantly. These are summarized in Table IV. Eighty- 
two percent (110/134) of the patients had an end- 
systolic LV diameter less than 40 mm. Indexed LV 
diameters were significantly smaller at most recent 
follow-up than they had been before the operation 
(p < 0.001) (Fig. 4). The mean grade of residual mitral 
regurgitation asrecorded at late follow-up was 0.44 _+ 
0.6. Only nine patients (6.4%) had grade 2 residual 
mitral insufficiency or greater. In all but one of these 
nine patients, the left atrial and LV sizes had reverted 
to normal and they received no medical therapy. 
Posterior versus bileaflet prolapse. Aortic cross- 
clamping time for repair of bileaflet prolapse was 
longer than that for correction of posterior prolapse 
alone (69.7 _+ 15.3 minutes vs 55.3 _+ 12.1 minutes; 
p < 0.001). However, no significant difference could 
be demonstrated between patients with posterior 
leaflet prolapse and those with anterior and poste- 
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Fig. 2. Actuarial curve of patients free from death and valve-related complications (percent) as a function 
of time after the initial operation (months). Numbers above x axis represent number of patients available 
for follow-up. 
rior prolapse regarding incidence of repair, residual 
leak, reoperation rate, and ventricular diameters. 
Degenerative versus rheumatic mitral regurgita- 
tion. Comparison of clinical findings and postoper- 
ative results in patients with degenerative versus 
rheumatic disease showed that the patients with 
rheumatic disease were younger, had a greater 
degree of residual regurgitation, higher transmitral 
gradients, and larger left atrial diameters. However, 
patients with rheumatic disease had smaller late 
postoperative end-diastolic diameters (Table V). 
Discussion 
The ultimate goal of surgical therapy for mitral 
regurgitation is to provide symptomatic relief and 
increased life expectancy at the lowest rate of com- 
plications. However, it is difficult to make a symp- 
tom-free patient feel better, and consideration must 
therefore be given to other parameters influencing 
the late outcome. As for any medical intervention, 
indications hould be based on weighing risk against 
benefit. Surgical correction may be advised only if 
survival and quality of life are improved in compar- 
ison with the disease's natural course. In this study, 
175 patients with severe chronic mitral regurgitation 
and no or mild symptoms underwent an operation; 
171 (98%) had valve repair, with three deaths 
(1.7%), for an actuarial survival of 98.2% and an 
event-free survival of 91.0% at 5 years. 
Population. In this series, patients in NYHA 
classes I and II had similar LV diameters before the 
operation, which confirms the poor reliability of the 
functional classification to identify patients at risk 
for the development of LV dysfunctionJ 5 The 
causes of mitral insufficiency in this series were 
representative of most western countries, with a 
predominance of degenerative disease and a low 
incidence of rheumatic valvular diseaseJ 6' 17 Pa- 
tients with associated coronary disease were ex- 
cluded to avoid interfering variables. 
Decision-making. The decision to operate was 
based on assessment of the severity of mitral regur- 
gitation and the feasibility of repair. Severity was 
judged by angiographic or Doppler parameters, 
echocardiographic left heart dimensions, and pul- 
monary artery pressure. Clinical parameters such as 
physiologic age, associated isease, lifestyle, and 
episodes of atrial fibrillation were also carefully 
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Fig. 3. Cardiac rhythm before the operation and at latest visit. AF, Atrial fibrillation. 
pondered. In this series, the mean preoperative 
end-systolic and end-diastolic LV diameters of, re- 
spectively, 40 and 65 mm, were lower than the 
guidelines suggested in the literature. <15, 18 This 
probably reflects our referring cardiologists' belief 
in the benefits of early surgical referral even for 
minimally disabled patients with severe chronic mi- 
tral insufficiency. Ability to distinguish between 
valves amenable to repair and those that are likely 
to require replacement is the cornerstone in the 
process of deciding the timing of operation. In this 
study, as in previous reports, preoperative two- 
dimensional echocardiography reliably predicted 
the feasibility of mitral valve repair. 7' 19 Indeed, only 
four patients (2%) required valve replacement when 
taking into account he three patients who under- 
went early reoperation for failed repair. Main echo- 
cardiographic features that decrease the likelihood 
of valve repair are anterior leaflet rigidity and 
restricted motion, particularly with a small anterior 
leaflet surface area. Calcification per se is not an 
absolute contraindication so long as it spares the 
leaflets, but it makes valve repair less predictable. 
Finally, what counts most in determining the feasi- 
bility of repair is the surgeon's personal experience 
with mitral valve reconstruction. 
Surgery. In the large majority of our patients 
(86%), mitral regurgitation was due to leaflet pro- 
lapse, in accordance with the predominance of 
degenerative alve disease in this series. Correction 
of anterior leaflet prolapse required the use of 
chordal transposition or chordal shortening in 26% 
and 22% of the cases, respectively. Correcting ex- 
treme forms of Barlow's disease with bileaftet pro- 
Table IV. Echocardiographic data 
Preoperative Follow-up p Value 
ESD 40.0 + 6.8 34.6 -+ 6.7 0.001 
IESD 22.0 ± 4.0 19.2 -+ 3.8 0.001 
EDD 64.8 ± 7.0 52.7 ± 7.4 0.001 
IEDD 35.9 + 4.7 29.3 -+ 3.9 0.001 
ESVI 40.0 ± 14.3 75.6 -+ 20.7 0.001 
EDVI 120.0 +- 25.9 43.6 -+ 10.5 0.001 
LAD 54.3 -+ 11.6 43.6 ± 10.5 0.001 
EF 64.3 -+ 10.5 62.7 ± 8.8 NS 
MR 3.4 -+ 0.5 0.44 -+ 0.6 0.001 
EF, Ejection fraction (%); ESD, left ventricular end-systolic diameter 
(mm); IESD, indexed left ventricular end-systolic diameter (mm/m2); 
EDD, left ventricular end-diastolic diameter (mm); IEDD, indexed left 
ventricular end-diastolic diameter (mm/m2); ESVI, left ventricular end- 
systolic volume index (ml/m2); EDVI, left ventricular end-diastolic volume 
index (ml/m2); LAD, left atrial diameter (mm); MR, mitral regurgitation 
(mean; grade 1 to 4). 
lapse and frequently commissural prolapse usually 
requires the combination of several techniques, as 
confirmed in the present study by the longer cross- 
clamp times in these patients compared with those 
with simple posterior prolapse. 2° Most important, 
the same spectrum of functional disorders and the 
same degree of reconstruction complexity can be 
found in the minimally disabled as in the more 
severely symptomatic patient. 
Survival. Few studies on the natural history of 
mitral regurgitation have been conducted. Ra- 
manathan and associates 21 reported nine deaths 
(22%) among 41 patients with pure mitral regurgi- 
tation in functional classes I and II during a 4-year 
follow-up. Delahaye and colleagues, 22describing 32 
patients with severe mitral regurgitation who were 
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and at latest follow-up measured by echocardiography. A, 
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not considered candidates for surgical repair as yet, 
reported seven deaths (22%), four of them sudden. 
These authors also demonstrated that despite an 
ejection fraction greater than 45%, the risk of 
cardiac death was not eliminated, because they 
found a 29% incidence of sudden death. 
Although our population may differ from the ones 
reported in the aforementioned studies, a survival of 
98% at 5 years observed in the present series compares 
favorably with the natural history of the disease. Re- 
ports on mitral valvuloplasty indicate an actuarial 
survival around 90% at 5 years for populations with 
predominantly functional class III and IV disease. 23-25 
Interestingly, in all these series, about half of late 
deaths were of cardiac origin, caused by congestive 
heart failure or arrhythmias. Also, it has recently been 
Table V. Degenerative versus rheumatic mitral 
regurgitation 
Degenerative Rheumatic 
(n = 26) (n = 128) 
Mean SD Mean SD p Value 
Age 53.7 12.9 41.15 16.3 <0.0001 
Preop. ESD 39.8 5.9 40.5 5.7 NS 
Preop. EDD 65.1 7.2 63.6 5.8 NS 
Preop. EF 65.3 10.8 60.0 7.4 <0.09 
Clamp time 62.4 16.0 63.7 16.5 NS 
Postop. LAD 42.8 10.3 49.8 9.6 <0.007 
Residual MR (1-4) 0.34 0.59 0.95 0.67 <0.0001 
Postop. ESD 35.3 6.5 32.8 4.1 NS 
Postop. EDD 53.7 6.4 49.9 4.5 <0.01 
Postop. EF 62.5 9.2 63.0 6.64 NS 
Mitral gradient 3.2 1.9 4.5 1.7 <0.006 
ESD, Left ventricular end-systolic diameter; EDD, left ventricular end- 
diastolic diameter; EF, ejection fraction; LAD, left atrial diameter; MR, 
mitral regurgitation. 
shown that in patients with mitral regurgitation, pre- 
operative functional class remained an independent 
predictor of operative and late survival. 26 
Morbidity and valve-related complications. A 
low rate of perioperative complications was ob- 
served in this series, the majority of them being 
minor. Had intraoperative transesophageal chocar- 
diographic monitoring been available in this study, 
the three early reoperations probably could have 
been avoided. One of these reoperations was neces- 
sitated by systolic anterior motion of the anterior 
leaflet in a patient with myxomatous degeneration 
and occurred before we began using the sliding 
leaflet repair, a technique that has virtually elimi- 
nated this complication. 27Sequential postoperative 
Doppler echocardiographic studies howed that mi- 
tral valve repair was stable and durable, inasmuch as 
most patients (93%) in our series had minimal or no 
mitral regurgitation at late follow-up. Residual re- 
gurgitation was more prevalent in patients with 
rheumatic disease, an observation that probably 
should lead to a more conservative approach, par- 
ticularly with restricted motion of the anterior leaf- 
let. 2°'23 On the other hand, in our experience, 
bileaftet prolapse, although requiring specific tech- 
niques, had the same incidence of reoperation or 
residual regurgitation as the more straightforward 
posterior prolapse. 
The 96.3% + 1.7% rate of freedom from throm- 
boembolism and the absence of anticoagulant-re- 
lated complications, for an event-free survival of 
91% at 5 years, are undisputable indicators of low 
valve-related morbidity. Moreover, significant re- 
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duction in left atrial size may account for the 83% 
incidence of sinus rhythm at follow-up (vs 70% 
before the operation) and the low incidence of 
thromboembolic complications. 
LV function. True functional improvement was 
demonstrated in this study inasmuch as the percent- 
age of patients in NYHA class I rose from 30% to 
87% as did the percentage of patients requiring no 
medical therapy, from 28% to 69%. Another finding 
of this study was the significant decrease in LV 
end-systolic and end-diastolic diameters and in- 
dexed LV volumes to normal values in almost all 
patients. Similar results were obtained by other 
investigators u ing cineangiography or echocardiog- 
raphy.28, 29 Several reports have demonstrated the 
prognostic value of end-systolic LV dimensions and 
ejection fraction. 18'3° Borow and coworkers 3°
showed that patients with mitral regurgitation who 
had an end-systolic volume index in excess of normal 
(>31 ml/m 2) had abnormal postoperative LV func- 
tion, proportional to the degree of enlargement. 
Postoperative ejection fraction has been shown to 
correlate well with outcome and to be predicted by 
preoperative echocardiographic ejection fraction as 
well as systolic LV diameter) 1 In the present series, 
82% of the patients had late LV systolic dimensions 
within normal range. Thus mitral valvuloplasty, in
the absence of severe symptoms, achieved the goal 
of preserving postoperative LV function and should 
guarantee an excellent late outcome. 
Limitations. No information could be gathered 
about the number of patients with minimal impair- 
ment who were not referred for surgical treatment 
because their mitral regurgitation was deemed un- 
repairable. The functional NYHA classification has 
recognized limitations that may have blurred the 
inclusion process. Ideally, patients hould have been 
objectively assessed with a standardized xercise test 
or measurement of peak oxygen consumption. Clear 
demonstration f the superiority of surgical treat- 
ment for patients with no symptoms or mild symp- 
toms would theoretically require a randomized trial 
comparing the outcomes of medically and surgically 
treated patients. However, it would have been im- 
practical to gather such a control group in our 
medical environment because the majority were 
referred for surgical treatment. 
Conclusions 
Surgical treatment can be advocated for severe 
mitral regurgitation regardless of symptoms, be- 
cause valve repair can be accurately predicted and 
performed in a large majority of patients with a low 
mortality and morbidity. An event-free survival of 
91% at 5 years, combined with a significant reduc- 
tion in left heart dimensions, low incidence of atrial 
arrhythmias, and residual eak, suggests that pa- 
tients with severe mitral regurgitation may benefit 
from surgical treatment at an early, compensated 
stage. These results must be confirmed by a longer 
period of observation and should be viewed against 
the background of a western type of population and 
each institution's surgical expertise with mitral valve 
repair beyond the learning curve. 
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Discuss ion 
Dr. Lawrence H. Cohn (Boston, Mass.). Dr. Dreyfus, 
you and your colleagues have presented some outstanding 
data on mitral valve repair. Along with similar studies, this 
information should allow us, with our cardiology col- 
leagues, to expand our pool of patients for mitral valve 
repair. It is one of the first papers of this kind that I have 
seen focusing on this particular symptomatic class. 
you have reporte d excellent results, with 1% mortality, 
freedom from death at 5 years of 98%, thromboembolism, 
and reoperation. It would have been helpful to have 
compared this with the natural history of a similar group 
(mild or no symptoms) who were treated medically, but I 
do not believe you have that opportunity any longer. 
To corroborate your results, I reviewed a personal 
series of 91 patients with class I and class II disease who 
underwent mitral valve repair just for floppy disease at the 
Brigham over the past 3 years. They had similar demo- 
graphics, although they were slightly older and about 15 % 
had concomitant coronary bypass. The operative mortality 
was zero. The thromboembolism and reoperation rates 
were exactly what you reported. My first question to you is 
this: Since you excluded associated operations, if you see 
a similar patient with myxomatous disease and concomi- 
tant coronary disease, do you still use the same indications 
for surgery that you mentioned in your paper, that is, a 
very early approach? 
You suggest that surgical treatment may be feasible for 
a patien t who has severe mitral regurgitation, o symp- 
toms, and totally normal LV function. Is that what you 
now do in your practice? Would you suggest that this now 
be an indication for surgery, even in the totally normal LV 
with normal dimensions? Most cardiologists in the United 
States would observe such patients with normal function 
and normal volumes until volume changes or slight de- 
pression of ejection fraction occurred before allowing us 
to see patients, despite the fact that there are changes in 
the LV with relatively few symptoms. For example, in your 
series, how many had totally normal LV function and how 
many had very severe depression of LV ejection fraction, 
let's say, less than 0.30? Also, if the echocardiogram 
exhibits very severe anterior/posterior prolapse, which 
would require a lot of work and maybe a higher likelihood 
of valve replacement, and the patient is totally free of 
symptoms, does that patient in your series now still get this 
early operation? Others, including me, have suggested 
that transient atrial fibrillation or new-onset atrial fibril- 
lation, despite good LV function, should be an indication 
for mitral valve repair. What have the preoperative and 
postoperative changes in atrial fibrillation been in this 
series? Finally, despite your using the rigid Carpentier 
ring for the annuloplasty, ou seldom used the sliding 
repair technique in conjunction with this. Would you 
please Comment on that? 
These are superb results. Ideally, these kinds of data will 
stimulate our cardiologists to consider earlier eferral of the 
symptom-free patient with severe mitral regurgitation. 
Dr. Dreyfus. Thank you, Dr. Cohn. Obviously we could 
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not do a study comparing natural history of mitral valve 
evolution as opposed to results with surgical treatment. 
Your first question dealt with myxomatous disease 
associated with coronary disease. Treatment would de- 
pend on the severity of the coronary disease and the 
ejection fraction. For such patients coronary disease 
would probably be the predominant reason to recommend 
surgical treatment. If not the case, such patients would 
probably not undergo an operation at such an early stage 
because they are widely known to be at risk. However, we 
do believe that whatever the lesions are, mitral valve 
repair should be based on the severity of the regurgitation. 
Totally normal LV function in combination with mitral 
regurgitation is a real problem. I do not think LV function 
should be taken into account with regard to symptoms 
because medical therapy can modify functional class. 
Most of the patients in western countries now have not 
only diuretics but also angiotensin-converting enzyme 
inhibitors, which can dramatically decrease the symptoms 
and allow the left ventricle to dilate silently. We do believe 
that regurgitation reaching the pulmonary veins at echo- 
cardiography is enough to predict and to indicate mitral 
surgery. As I have said before, patients may remain 
symptom-free for a long time although their ventricular 
size has increased. However, if a patient has a totally 
normal eft ventricle we would perhaps adopt a strategy of 
close follow-up and recommend surgical treatment when 
the end-systolic diameter reached 40 mm. I do not believe 
there were any ejection fractions in this series below 40%. 
Concerning the complexity of the lesions, so long as 
those patients have degenerative disease, we believe that 
mitral valve repair can be undertaken. Like Dr. Lessana, 
however, we are aware that there might be a risk of mitral 
valve replacement according to the complexity of the 
lesions, even in patients who are totally free of symptoms, 
and this risk would not be accepted by cardiologists here 
or in Europe. 
We have not seen a significant change in the prevalence of
atrial fibrillation in these patients before and after the 
operations. The infrequent use of the sliding repair is due to 
the multicenter ffect. This technique was used in one center 
but not in the others. I think this policy has to be reconsid- 
ered. Three patients had systolic anterior motion, and it has 
been well demonstrated by Carpentier's group that the 
nonperformance of sliding repair is a risk factor for systolic 
anterior motion when the patient has a myxomatous valve 
and a high posterior leaflet. 
Dr. Alain F. Carpeutier (Paris, France). Because pa- 
tients with severe mitral valve insufficiency can have a 
normal ife for several years, they are not easy to convince, 
nor are the cardiologists. It seems to me that there are two 
conditions, the first being that we must be able to guar- 
antee that we will be able to repair the valve rather than 
to replace it. Now comes my first question. I noticed that 
64 of your patients had had valve replacement. Why was it 
not possible to predict hat they could not have had a valve 
repair? Although the proportion is small, the question is 
important, particularly with the availability of echocardi- 
ography. 
The second condition is to have a near-zero mortality. 
Although your mortality was less than 1.7%, you had at 
least two deaths that were due to so-called low cardiac 
output, or heart failure, which is a bit surprising for this 
particular group of patients. Any deaths in this particular 
group would be carefully analyzed, and I would like to 
• know a little bit more about these two deaths. 
One important point was not emphasized: this is a 
multicenter study done by different surgeons, and it shows 
that this operation can be carried out safely by different 
surgeons and with reliable results. 
Dr. Dreyfus. I would like to thank Professor Carpentier 
for his kind remarks and remind you that we have all 
learned mitral repair from him, in France at least. 
Concerning the dimensions of the left ventricle, many 
cardiologists, like Mudge and Gaasch, have stressed that a 
rise in end-systolic diameter above 45 mm and an abnor- 
mal ejection fraction indicate ventricular dysfunction. 
Perhaps cardiologists do write things they do not believe, 
but at least they stress that ventricular dysfunction occurs 
very quickly, as soon as the LV end-systolic dimension 
increases mildly; therefore the absence of symptoms does 
not mean much. 
To answer your first question, the 64 valve replacements 
were not done in patients who had no symptoms or mild 
symptoms. Over a period of 5 years, 584 patients under- 
went mitral valve operations. Among those, a vast major- 
ity had mitral valve repair and 64 had valve replacement. 
These statistics have nothing to do with class I or II 
disease. 
Concerning the second question about the deaths, of 
course this is a real problem. One of the patients had a 
myocardial infarction, probably because of inadequate 
myocardial protection, and the other had LV dysfunction. 
Both of these patients, although aving no symptoms or 
mild symptoms, had extremely enlarged left ventricles. 
The first one had a 78 mm end-diastolic dimension and 
the other one had an 83 mm dimension. These two 
patients emphasize the point that the ventricles can 
already be very dilated even if the patient has no symp- 
toms or mild symptoms. Such patients can be very sick and 
operating on them is risky. 
Dr. Manuel J. Antunes (Coirnbra, Portugal). We have 
also been pushing our indications for mitral valve repair 
toward much earlier operations. Under the advice and 
encouragement of Professor Ballo, whose name remains 
forever connected to the mitral valve, we have undertaken 
repair on some patients who had mild or even minimal 
mitral valve regurgitation and had severe arrhythmias that 
were uncontrollable by medical therapy. These were mi- 
tral click syndromes. We repaired these valves by resecting 
areas of prolapsed leaflets or transposing chordae. The 
preliminary results were published some time ago and 
were encouraging. My question is this: Do you have any 
experience with mitral repair in this type of disease, and 
would you consider this as an indication for valve surgery 
in this type of patient? 
Dr. Dreyfus. Thank you, Dr. Antunes. I'm sorry, but I 
do not have any data on that. We are looking forward in 
the future to answering this question, but not in this series. 
